The proposed Integris Medtech IPO has been revised to reduce its fresh issue from ₹925 crore to ₹600 crore, with debt repayment remaining the main use of the capital. The changes, detailed in an addendum to the draft prospectus and disclosed on October 22, 2026, also scale back planned share sales by promoters.
Key Takeaways
- The proposed fresh issue has been reduced by ₹325 crore.
- About ₹509.85 crore is earmarked for repayment or prepayment of subsidiary borrowings.
- Two promoters have withdrawn their planned share sales, while Evercure Holdings has reduced its offer.
Table of Contents
- Integris Medtech IPO prioritizes debt repayment
- Promoters reduce planned sales of existing shares
- Medical devices and laboratory solutions underpin operations
- Conclusion
Integris Medtech IPO prioritizes debt repayment
Approximately 85% of the revised ₹600 crore fresh issue is intended for repayment or prepayment of borrowings across wholly owned and step-down subsidiaries. The allocation covers Translumina Therapeutics, Transhealth, CPC Diagnostics, Chemopharm and Research Instruments.
The planned use of proceeds makes debt reduction the central purpose of the smaller capital raise. Repayment could lower future finance costs and improve financial flexibility, but those benefits remain prospective: the offering and the proposed repayments have not been completed.
SEBI’s October 2025 draft offer document record establishes the earlier filing history of the proposed IPO. That historical record is separate from the October 2026 addendum setting out the revised issue size and debt allocation.
| Item | Details |
|---|---|
| Original proposed fresh issue | ₹925 crore |
| Revised proposed fresh issue | ₹600 crore |
| Reduction in fresh capital sought | ₹325 crore |
| Planned subsidiary debt repayment | Approximately ₹509.85 crore |
Promoters reduce planned sales of existing shares
Co-founders and promoters Gurmit Singh Chugh and Punita Sharma have withdrawn their proposed offer-for-sale participation. They would therefore retain their existing shares through the proposed transaction.
Promoter Evercure Holdings Pte. Ltd has reduced its planned offer for sale to up to 10,837,266 equity shares.
The distinction between the two components matters: newly issued shares raise capital for the company, while an offer for sale generates proceeds for selling shareholders. The ₹600 crore figure describes the revised fresh issue, not the total value of the combined offering.
Medical devices and laboratory solutions underpin operations
Integris operates in cardiovascular devices and laboratory solutions. Its cardiovascular portfolio includes drug-eluting stents, drug-coated balloons, complex coronary intervention products and vascular access solutions. Its laboratory business serves clinical, research and industrial laboratories.
The business began with sales of cardiology products and expanded into advanced manufacturing, including the Yukon drug-eluting stent. It has manufacturing facilities in India, Germany and the Netherlands.
Conclusion
The revised Integris Medtech IPO seeks less fresh capital while retaining a substantial debt-repayment allocation. The remaining milestones are completion of the proposed offering and execution of the planned repayments; neither should be treated as completed.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
